FindTrial
Sign In

Product Name: CG5503

6 trials

Sponsors

Johnson & Johnson Pharamceutical Research & Development, L.L.C., Johnson & Johnson Pharamceutical Resarch & Development, L.L.C, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH

Conditions

Chronic pain due to knee or hip osteoarthritis or low back pain of benign origin MedDRA version: 8.1 Level: LLT Classification code 10049475 Term: Chronic painPain MedDRA version: 8.1 Level: LLT Classification code 10033371 Term: PainPostoperative pain following abdominal hysterectomy MedDRA version: 8.1 Level: LLT Classification code 10000075 Term: Abdominal hysterectomymalignant tumor related pain MedDRA version: 8.1 Level: LLT Classification code 10058019 Term: Cancer painmoderate to severe pain MedDRA version: 8.1 Level: LLT Classification code 10033371 Term: Painpain MedDRA version: 8.1 Level: LLT Classification code 10033371 Term: Pain

Phase 3

A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease - n.a.
Active, not recruitingEUCTR2006-004514-40-GB
Johnson & Johnson Pharamceutical Research & Development, L.L.C.Pain MedDRA version: 8.1 Level: LLT Classification code 10033371 Term: Pain
Start: 2007-02-14Target: 624Updated: 2017-08-21

Unknown Phase

A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR* and Oxycodone CR in Subjects with Chronic Pain
Active, not recruitingEUCTR2006-003482-14-IE
Johnson & Johnson Pharamceutical Resarch & Development, L.L.CChronic pain due to knee or hip osteoarthritis or low back pain of benign origin MedDRA version: 8.1 Level: LLT Classification code 10049475 Term: Chronic pain
Start: 2007-02-23Target: 1075Updated: 2012-05-29
A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension
Active, not recruitingEUCTR2006-004513-18-GB
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.pain MedDRA version: 8.1 Level: LLT Classification code 10033371 Term: Pain
Start: 2007-02-14Target: 1100Updated: 2012-03-19
Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release or Oxycodone Immediate Release in Subjects With Chronic Pain from Low Back Pain or Osteoarthritis of the Hip or Knee - n.a
Active, not recruitingEUCTR2006-003278-93-GB
Johnson & Johnson Pharamceutical Research & Development, L.L.C.moderate to severe pain MedDRA version: 8.1 Level: LLT Classification code 10033371 Term: Pain
Start: 2007-01-31Target: 875Updated: 2012-03-19
A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignant tumor-related pain - n.a.
Active, not recruitingEUCTR2006-004997-28-CZ
Grünenthal GmbHmalignant tumor related pain MedDRA version: 8.1 Level: LLT Classification code 10058019 Term: Cancer pain
Start: 2007-03-15Target: 573Updated: 2012-08-21
A randomized, double-blind, parallel-arm, placebo- and comparator-controlled trial of the efficacy and safety of multiple doses of immediate-release (IR) CG5503 for postoperative pain following abdominal hysterectomy - n.a.
Active, not recruitingEUCTR2006-004998-95-HU
Grünenthal GmbHPostoperative pain following abdominal hysterectomy MedDRA version: 8.1 Level: LLT Classification code 10000075 Term: Abdominal hysterectomy
Start: 2007-08-08Target: 855Updated: 2012-03-19